TRODELVY

Google image searchProduct monograph

Active ingredient

sacituzumab govitecan, 180 MG/VIAL

DIN: 02520788

Dosage form(s): POWDER FOR SOLUTION

Route(s) of administration: INTRAVENOUS

Schedule: Prescription / Schedule D

Company: GILEAD SCIENCES CANADA INC

Date: 22-NOV-2021

ATC:

Pharmaceutical standard: MFR

Search on Google